VetSRev
Database of veterinary systematic reviews
Database of veterinary systematic reviews
Urology (2021) 148: 8–25
DOI: 10.1016/j.urology.2020.10.024
There is growing evidence suggesting cannabinoids may provide suitable alternatives to conventional treatments in an increasing number of clinical settings. This review evaluates how cannabinoids are used to treat certain benign urological pathologies and to clarify the clinical value of this data. This review includes 62 papers and was undertaken per PRISMA’s guidelines, it evidences the therapeutic potential of cannabinoids in the management of specific benign urological diseases, most notably neurogenic bladder dysfunction (clinical studies), renal disease (animal studies), and interstitial cystitis (animal studies). However, whilst cannabinoids are increasingly used, they cannot be considered reliable alternatives to more recognised treatments.
Taylor, C., & Birch, B. (2021). Cannabinoids in urology. which benign conditions might they be appropriate to treat: a systematic review. Urology, 148, 8–25. https://doi.org/10.1016/j.urology.2020.10.024 reviews, animal models, man, systematic reviews, human diseases, clinical aspects, kidney diseases, Non-communicable Human Diseases and Injuries [VV600], Animal and in vitro Models for Pharmaceuticals [VV450], Animal Models of Human Diseases [VV400], clinical picture, bladder diseases, cannabinoids, cystitis, kidney disorders, nephropathy, Non-food/Non-feed Plant Products [SS200], Pharmacology [VV730], renal diseases, urinary tract diseases, Cannabinoids, Urology